跳至主要内容
临床试验/NCT00362349
NCT00362349已完成3 期

A Single-arm, Open Label, Multi-centre Study Evaluating the Efficacy and Safety of Ig NexGen 10% in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

CSL Limited8 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2007年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
CSL Limited
入组人数
19
试验地点
8
主要终点
Efficacy

研究概览

简要总结

Idiopathic Thrombocytopenic Purpura (ITP) is an autoimmune bleeding disorder characterised by isolated low platelet counts. The aim of treating patients with ITP is to increase the platelet concentration and reduce the risk of bleeding. A number of controlled multi-centre studies have demonstrated that Intravenous Immunoglobulin (IVIg) therapy produces a rapid rise in platelet counts within a 24 to 72 hour period. This study will evaluate the efficacy and safety of Ig NextGen 10% in adult patients with ITP.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • clinical diagnosis of ITP
  • platelet count of <50 X 10^9

排除标准

  • planned splenectomy
  • previous non-responders to IVIg treatment
  • known or suspected hypersensitivity or previous evidence of severe side effects to immunoglobulin therapy
  • patients who have received treatment with:
  • IVIg or anti-D immunoglobulin
  • immunosuppressive, any other immunomodulatory drug(s) or other active treatment(s)for ITP within three weeks prior to first day of study drug administration
  • patients who have received IV administration of steroids OR have had a change of oral corticosteroid treatment OR danazol within 15 days prior to first day of study drug administration.

研究组 & 干预措施

1

Experimental

IVIg

干预措施: IgNextGen 10% (Drug)

结局指标

主要结局

Efficacy

时间窗: 90 days

次要结局

  • Safety(97 days)

研究者

发起方
CSL Limited
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验